Clinical outcome with concurrent or layered treatment with radium-223 and abiraterone: A retrospective study of real-world experience with patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

被引：1
|
作者：
George, Daniel J.
Sternberg, Cora N.
Sartor, A. Oliver
Saad, Fred
Tombal, Bertrand F.
Miller, Kurt
Kalinovsky, Jan
Jiao, XiaoLong
Tangirala, Krishna
Higano, Celestia S.
机构：
[1] Duke Canc Inst, Durham, NC USA
[2] Weill Cornell Med, Englander Inst Precis Med, New York, NY USA
[3] Tulane Med Sch, New Orleans, LA USA
[4] Univ Montreal, Ctr Hosp Univ Montreal, Montreal, PQ, Canada
[5] Clin Univ St Luc, Brussels, Belgium
[6] Charite, Dept Urol, Berlin, Germany
[7] Bayer Healthcare Pharmaceut Inc, Basel, Switzerland
[8] Bayer HealthCare Pharmaceut Inc, Whippany, NJ USA
[9] Univ Washington, Seattle, WA 98195 USA
[10] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 07期
关键词：
D O I：
10.1200/JCO.2019.37.7_suppl.253
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
253
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Practical recommendations for radium-223 treatment of metastatic castration-resistant prostate cancer
    Yong Du
    Ignasi Carrio
    Giuseppe De Vincentis
    Stefano Fanti
    Harun Ilhan
    Caroline Mommsen
    Egbert Nitzsche
    Francis Sundram
    Wouter Vogel
    Wim Oyen
    Val Lewington
    European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44 : 1671 - 1678
  • [32] Radium-223 for the treatment of metastatic castration-resistant prostate cancer: A window of opportunity
    Gomez-Veiga, F.
    Alvarez-Ossorio, J. L.
    Carballido-Rodriguez, J.
    Juarez-Soto, A.
    Rodriguez-Antolin, A.
    Cozar-Olmo, J. M.
    ACTAS UROLOGICAS ESPANOLAS, 2018, 42 (10): : 616 - 624
  • [33] Safety outcomes and pain responses in the REASSURE observational study of radium-223 (Ra-223) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
    Conti, Peter
    George, Saby
    Tomaszewski, Jeffrey
    Song, Daniel
    Harshman, Lauren
    Nordquist, Luke
    Sandstrom, Per
    Bayh, Inga
    Babajanyan, Svetlana
    Sartor, Oliver
    JOURNAL OF NUCLEAR MEDICINE, 2020, 61
  • [34] Experience with radium-223 as a systemic treatment for patients (pts) with castration-resistant prostate cancer (CRPC) out of a clinical trial in Spain
    Grande, E.
    Pinto, A.
    Duran, I.
    Lopez-Criado, P.
    Suarez, C.
    Gonzalez-Larriba, J. L.
    Sanchez-Lorenzo, L.
    Maroto, P.
    Lainez, N.
    Gonzalez del Alba, A.
    Saez, M. I.
    Alonso-Gordoa, T.
    Perez-Valderrama, B.
    Puente, J.
    Morales, R.
    Esteban, E.
    Manneh, R.
    Benedetti, J.
    Carles-Galceran, J.
    Castellano, D.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S488 - S489
  • [35] Practical recommendations for radium-223 treatment of metastatic castration-resistant prostate cancer
    Du, Yong
    Carrio, Ignasi
    De Vincentis, Giuseppe
    Fanti, Stefano
    Ilhan, Harun
    Mommsen, Caroline
    Nitzsche, Egbert
    Sundram, Francis
    Vogel, Wouter
    Oyen, Wim
    Lewington, Val
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 (10) : 1671 - 1678
  • [36] Real-world treatment with abiraterone acetate in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC)
    Boegemann, Martin
    Hatzinger, Martin
    Hercher, Dirko
    Matus, Geoffrey
    Everaert, Els Grieta
    Dopchie, Catherine
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [37] Clinical outcomes and treatment patterns in REASSURE : planned interim analysis of a real-world observational study of radium-223 in metastatic castration-resistant prostate cancer
    Higano, Celestia S.
    George, Daniel J.
    Shore, Neal D.
    Sartor, Oliver
    Miller, Kurt
    Conti, Peter S.
    Sternberg, Cora N.
    Saad, Fred
    Sade, Juan Pablo
    Bellmunt, Joaquim
    Smith, Matthew R.
    Chandrawansa, Kumari
    Sandstroem, Per
    Verholen, Frank
    Tombal, Bertrand
    ECLINICALMEDICINE, 2023, 60
  • [38] Fracture risk in men with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (Ra 223)
    Hijab, A.
    Tunariu, N.
    Tovey, H.
    Alonzi, R.
    Tree, A.
    Staffurth, J.
    Blackledge, M.
    Padhani, A. R.
    Stidwill, H.
    Finch, J.
    Chatfield, P.
    Perry, S.
    Koh, D-M.
    Hall, E.
    Parker, C.
    ANNALS OF ONCOLOGY, 2020, 31 : S539 - S539
  • [39] Abiraterone acetate in metastatic castration-resistant prostate cancer – the unanticipated real-world clinical experience
    Darren M. C. Poon
    Kuen Chan
    S. H. Lee
    T. W. Chan
    Henry Sze
    Eric K. C. Lee
    Daisy Lam
    Michelle F. T. Chan
    BMC Urology, 16
  • [40] Real World Outcomes in Patients With Metastatic, Castration-Resistant Prostate Cancer Treated With Radium-223 in Routine Clinical Practice in Sweden
    Stattin, Par
    Westerberg, Marcus
    Lissbrant, Ingela Franck
    Eriksson, Marie Hjalm
    Kjellman, Anders
    Ullen, Anders
    Vassilev, Zdravko
    Sandstrom, Per
    Weinrib, Rachel
    Martinez, David
    Garcia-Albeniz, Xabier
    CLINICAL GENITOURINARY CANCER, 2023, 21 (01) : 107.e1 - 107.e9
12345